New formulations of drugs in epilepsy

Bibliography

• SMITH DB, MATTSON RH, CRAMER JA, COLLINS JF,NOVELLY RA, CRAFT B: Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia (1987) 28\(Suppl. 3):S50–58.
   Google Scholar
• YUKAWA E: Optimization of antiepileptic drugtherapy. OM. Pharmacokin. (1996) 31:120–130.
   PubMedGoogle Scholar
• POST RM, TRIMBLE MR, PIPPENGER CE: Clinical Use of Anticonvulsants in Psychiatric Disorders. Demos Publishers, New York City, USA (1989).
   Google Scholar
• BARRY JJ: Psychiatric uses for anticonvulsants. In: Merritt-Putnam Lectures, CME Monograph: Update on Epilepsy Management and Emerging Uses of Anti-epileptic Drugs. American Epilepsy Society, West Hartford, CN, USA (1999)89–104.
   Google Scholar
• MORSELLI PL: In: Anti-Epileptic Drugs (4th Edition). Levy RH, Mattson RH, Meldrum BS (Eds.), Raven Press, New York, USA (1995):515.
   Google Scholar
• RIVA R, ALBANI F, AMBROSETTO G et al.: Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia. (1984) 25(4):476–481.
   PubMed Web of Science ®Google Scholar
• CRAMER JA, MATTSON RH, PREVEY ML, SCHEYER RD, OUELLETE VL: How often is medication taken as prescribed? JAMA (1989) 261 (22):3273–3277.
   PubMed Web of Science ®Google Scholar
• Data on file. Shire Richwood, Inc. Florence, KY 41042. (Tel.: +1 800 536 7878).
   Google Scholar
• CLOYD JC, KRIEL RL, JONES-SAETE CM et al: Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J. Pediatr. (1992) 120:634–638.
   PubMedGoogle Scholar
• GARNETT WR, LEVY B, MCLEAN AM et al.: Pharmacoki-netic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Epilepsia (1998) 39(3):274–279.
   PubMed Web of Science ®Google Scholar
• MIRZA WU, RAK IW, THADANI VM et al.: Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures. Neurology. (1998) 51:1727–1729.
   PubMed Web of Science ®Google Scholar
• •Prospective evaluation of the efficacy and pharmacokinetics of CBTL.
   Google Scholar
• THEEUWES F, SWANSON DR, GUITTARD G, AYER A, KHANNA S: Osmotic delivery systems for the adreno-ceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administra-tion. Br. J. Clin. Pharmacol (1985) 19:69S–76S.
   Google Scholar
• THE TEGRETOL OROS OSMOTIC RELEASE DELIVERY SYSTEM STUDY GROUP: Double-blind crossover comparison of Tegretol-XR and Tegretol in patients with epilepsy. Neurology (1995) 45:1703–1707.
   PubMedGoogle Scholar
• •Prospective evaluation of the efficacy and pharmacokinetics of TXR.
   Google Scholar
• WILDING IR, DAVIS SS, HARDY JG et al.: Relationship between systemic drug absorption and gastrointes-tinal transit after the simultaneous oral administra-tion of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. Br. J. Clin. Pharmacol (1991) 32(5):573–579.
   PubMedGoogle Scholar
• ••Best documentation of effect of gastrointestinal transit timeon efficacy of sustained release medication.
   Google Scholar
• MCKEE PJ, BLACKLAW J, BUTLER E, GILLHAM RA, BRODIEMJ: Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double- dummy comparison in epileptic patients. Br. J. Clin. Pharmacol. (1991) 32:99–104.
   PubMedGoogle Scholar
• STEVENS RE, LIMSAKUN T, EVANS G, MASON DH: Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XID. J. PharmacoL Sci. 87 (12):1531–1534.
   Google Scholar
• •Good pharmacokinetic comparison of these two drugs.
   Google Scholar
• FRANK LM, ENLOW T, HOLMES G et al.: Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia (1999) 10(7)973–979.
   Google Scholar
• •Documents the efficacy of lamotrigine in absence seizures.
   Google Scholar
• MIKATI MA, HOLMES GL: Lamotrigine in absence and primary generalized epilepsies. J. Child Neurol. (1997) 12 (Suppl. 1):S29–S37.
   Google Scholar
• MOTTE J, TREVATHAN E, ARVIDSSON JF, BARRERA MN, MULLENS EL, MANASCO P: Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. New Engl. J. Med. (1997) 337(25):1807–1812.
   PubMed Web of Science ®Google Scholar
• •Establishes Lamictal's efficacy in this seizure syndrome.
   Google Scholar
• DULAC 0, KAMINSKA A: Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes. J. Child Neurol (1997) 12 (Suppl. 1):S23–S28.
   Google Scholar
• SCHLUMBERGER E, CHAVEZ F, PALACIOS L, REY E, PAJOBN, DULAC 0: Lamotrigine in treatment of 120 children with epilepsy. Epilepsia (1994) 35(2):359–367.
   PubMed Web of Science ®Google Scholar
• DOOSE DR, WALKER SA, SCOTT W et al: The compara-tive bioavailability of topiramate from two investiga-tional pediatric sprinkle formulations relative to a Tablet formulation. Epilepsia (1996) 37 (Suppl. 5):112.
   Google Scholar
• DOOSE DR, WALKER SA, BALDASSARRE J: The effect offood on the oral bioavailability of topiramate from an investigational paediatric sprinkle formulation. Epilepsia (1997) 38 (Suppl. 3):147.
   Google Scholar
• SACHDEO RC, GLAUSER TA, RITTER F, REIFE R, LIM P,PLEDGER G: A double-blind, randomized trial of topira-mate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology (1999) 52 (9) :1882–1887.
   PubMed Web of Science ®Google Scholar
• •Documents topiramates efficacy in this epilepsy syndrome.
   Google Scholar
• ELTERMAN RD, GLAUSER TA, WYLLIE E, REIFE R, WU SC, PLEDGER G: A double-blind, randomized trial of topira-mate as adjunctive therapy for partial onset seizures in children. Topiramate YP Study Group. Neurology (1999) 52 (7):1338–1341.
   PubMed Web of Science ®Google Scholar
• BITON V, MONTOURIS GD, RITTER F et al. A random- ized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology (1999) 52(7):1330–1337.
   PubMed Web of Science ®Google Scholar
• GLAUSER TA, CLARK PO, STRAWSBURG R: A pilot study of topiramate in the treatment of infantile spasms. Epilepsia (1998) 39(12):1324–1328.
   PubMed Web of Science ®Google Scholar
• GLAUSER TA: Topiramate use in pediatric patients. Can. J. Neurol Sci. (1998) 25 (3):S8–S12.
   Google Scholar
• •Good review of topiramate responsive seizure types.
   Google Scholar
• HAUSER WA, HESDORFFER DC: Incidence and prevalence. In: Epilepsy: Frequency, Causes and Consequences. Hauser WA, Hesdorffer DC (Eds.), Demos Publications, New York, USA (1990):1–51.
   Google Scholar
• LOWENSTEIN DH: Seizures and status epilepticus. In:Current Practice of Emergency Medicine (2nd Edition). Callaham ML (Ed.), BC Decker, Philadelphia, USA (1990:307–313.
   Google Scholar
• CRANFORD RE, LEPPIK IE, PATRICK B et al.: Intravenousphenytoin in acute treatment of seizures. Neurology (1979) 29:1476–1479.
   Google Scholar
• WHELESS, JW: Treatment of acute seizures and status epilepticus in children. Resident Staff Physician (1999) 45 (Suppl. 10). (In Press).
   Google Scholar
• ••Good review of current treatment.
   Google Scholar
• BROWNE TR, KUGLER AR, ELDON MA: Pharmacology and pharmacokinetics of fosphenytoin. Neurology (1996) 46\(Suppl. 1):S3–S7.
   Google Scholar
• SMITH RD, BROWN BS, MAHER RW, MATIER WL: Pharma- cology of ACC-9653 (phenytoin prodrug). Epilepsia (1989) 30\(Suppl. 2):515–521.
   Google Scholar
• AWEEKA FT, GOTTWALD MD, GAMBERTOGLIO JG et al.: Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia (1999) 40(6)777–782.
   Google Scholar
• FISCHER JH, CWIK MJ, LUER MS, SIBLEY CB, DEYO KL: Stability of fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes. Ann. Pharmacother. (1997) 31:533–539.
   PubMedGoogle Scholar
• WHELESS JW: Pediatric use of intravenous and intramuscular phenytoin: lessons learned. J. Child Neurol (1998) 13 (Suppl. 1):S11–514.
   Google Scholar
• •Good review of this drug's historical use.
   Google Scholar
• JAMERSON BD, DUKES GE, BROUWER KLR, DONN KH, MESSENHEIMER JA, POWELL JR: Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy (1994) 14(1)47–52.
   Google Scholar
• UTHMAN BM, WILDER BJ, RAMSAY RE: Intramuscular use of fosphenytoin: an overview. Neurology (1996) 46\(Suppl. 1):S24–S28.
   Google Scholar
• FIERRO LS, SAVULICH DH, BENEZRA DA: Safety of fosphenytoin sodium. Am. J. Health-Syst. Pharm. (1996) 53:2707–2712.
   PubMed Web of Science ®Google Scholar
• JOHNSON NE, DOYLE JJ: A stepwise approach to performing a preliminary pharmacoeconomic analysis: Focus on fosphenytoin. Pharm. Ther. (1996):611–628.
   Google Scholar
• MARCHETTI A, MAGAR R, FISCHER J, SLOAN E, FISCHER P:A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx®) versus intravenous phenytoin (Dilantin®) in hospital emergency depart-ments. Clin. Ther. (1996) 18(5):953–966.
   PubMed Web of Science ®Google Scholar
• O'BRIEN TJ, CASCINO GD, SO EL, HANNA DR: Incidenceand clinical consequences of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology (1998) 51:1034–1039.
   PubMed Web of Science ®Google Scholar
• MATTSON RH: Parenteral andepilepticianticonvulsant drugs. Neurology (1996) 46\(Suppl. 1):S8–513.
   Google Scholar
• RAMSAY RE, DETOLEDO J: Intravenous administration of fosphenytoin: options for the management of seizures. Neurology (1996) 46\(Suppl. 1):S17–S19.
   Google Scholar
• DULAC 0, ARTHUIS M: Open trials with valproate in epilepsy. Epilepsia (1984) 25 (Suppl. 1):523–531.
   Google Scholar
• HOLLE LM, GIDA BE, COLLINS DM: Valproate in status epilepticus. Ann. Pharmacother. (1995) 29:1042–1044.
   PubMedGoogle Scholar
• MARLOW N, COOKE RWI: Intravenous sodium valproate in the neonatal intensive care unit. Fourth International Symposium on Sodium Valproate and Epilepsy. Royal Soc. Med. Intern. Congr. Symp. Ser. (1989) 152:208–210.
   Google Scholar
• PRICE DJ: Intravenous valproate: experience in neurosurgery. Fourth International Symposium on Sodium Valproate and Epilepsy. Royal Soc. Med. Intern. Congr. Symp. Ser. (1989) 152:197–203.
   Google Scholar
• DEVINSKY 0, LEPPIK I, WILLMORE LJ et al.: Safety of intravenous valproate. Ann. Neurol (995) 38:670–674.
   Google Scholar
• •Establishes general safety of this treatment.
   Google Scholar
• RAMSAY RE, UTHMAN B, LEPPIK IE et al: The tolerability and safety of valproate sodium injection given as an intravenous infusion. J. Epilepsy (1997) 10:187–193.
   Google Scholar
• WHELESS JW, VENKATARAMAN V: Safety of high intravenous valproate loading doses in epilepsy patients. J. Epilepsy (1998) 11(6):319–324.
   Google Scholar
• ••Establishes iv. loading dose of valproate.
   Google Scholar
• NARITOKU DK, MUEED S: Intravenous loading of valproate for epilepsy. Clin. Neuropharmacol (1999) 22(2):102–106.
   PubMedGoogle Scholar
• VENKATARAMAN V, WHELESS JW: Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res. (1999) 35:147–153.
   PubMed Web of Science ®Google Scholar
• HOVINGA CA, CHICELLA MF, ROSE DF, EADES SK, DALTON JT, PHELPS SJ: Use of intravenous valproate in three pediatric patients with nonconvulsive or convul-sive status epilepticus. Ann. Pharmacother. (1999) 33:579–584.
   PubMedGoogle Scholar
• Treatment of convulsive status epilepticus:Recommendations of the Epilepsy Foundation of America's Group on Status Epilepticus. JAMA (1993) 270:854–859.
   PubMed Web of Science ®Google Scholar
• SCHMIDT D: Benzodiazepines: diazepam. In: Anti-Epileptic Drugs (4th Edition). Levy RH, Mattson RH, Meldrum BS (Eds.), Raven Press, New York, USA (1995)705–724.
   Google Scholar
• DHILLON S, OXLEY J, RICHENS A: Bioavailability of diazepam after intravenous, oral and rectal admini-stration in adult epileptic patients. Br. J. Clin. Pharmacal. (1982) 13:427–432.
   PubMedGoogle Scholar
• MOOLEANR F, BAKKER S, VISSER J, AND HUIZINGA T:Biopharmaceutics of rectal administration of drugs in Exp. Opin. Pharmacother. (1999) 1(1) man IX. Comparative biopharmaceutics of diazepam after single rectal, oral, intramuscular and intrave-nous administration in man. Intern. J. Pharmacal. (1980) 5:127–137.
   Google Scholar
• GARRATTINI S, MARCUCCI F, MORSELLI PL, MUSSINI E: The significance of measuring blood levels of benzodi-azepines. In: Biological Effects of Drugs in Relation to their Plasma Concentrations. Davies, Prichard (Eds.), MacMillan, London, UK (1973):211–225.
   Google Scholar
• FRANZONI E, CARBONI C, LAMBERTINI A: Rectal diazepam: a clinical and EEG study after a single dose in children. Epilepsia (1983) 24:35–41.
   PubMedGoogle Scholar
• MILLIGAN N, DHILLON S, OXLEY J, RICHENS A: Absorp-tion of diazepam from the rectum and its effect on interictal spikes in the EEG. Epilepsia (1982) 23:323–331.
   PubMedGoogle Scholar
• DIECKMANN RA: Rectal diazepam for prehospital pediatric status epilepticus. Ann. Emergency Med. (1994) 23:216–224.
   PubMed Web of Science ®Google Scholar
• MILLIGAN N, DHILLON SO, RICHENS A, OXLEY J: Rectaldiazepam in the treatment of absence status: a pharmacodynamic study. J. Neurol. Neurosurg. Psychiat. (1981) 44:914–917.
   PubMedGoogle Scholar
• REMY C, JOURDIL N, VILLEMAIN D, FAVEL P, GENTON P: Intrarectal diazepam in epileptic adults. Epilepsia (1992) 33(2):353–358.
   PubMedGoogle Scholar
• MITCHELL WG: Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome and treatment. Epilepsia (1996) 37 (Suppl. 1):S74–S80.
   Google Scholar
• FRITZ E, DREIFUSS N, ROSMAN P, CLOYD JC et al.: A comparison of rectal diazepam gel and placebo for acute repetitive seizures. New Engl. J. Med. (1998) 338(26)1869–1875.
   Google Scholar
• •Document safety and efficacy of out of hospital seizure treatment.
   Google Scholar
• CEREGHINO JJ, MITCHELL WG, MURPHY J, KRIEL RL, ROSENFELD WE, TREVATHAN E: Treating repetitive seizures with a rectal diazepam formulation: A randomized study. The North American Diastat Study Group. Neurology (1998) 51 (5) :1274–1282.
   Google Scholar